Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.006
Neutral
RSI(14)
32.590
Neutral
STOCH(KDJ)(9,3,3)
60.279
Buy
ATR(14)
0.088
High Vlolatility
CCI(14)
-27.407
Neutral
Williams %R
84.524
Oversold
TRIX(12,20)
-1.997
Sell
StochRSI(14)
100.000
Buy
Search
Cardiff Oncology Inc
CRDFAdd to Watchlist
0.855USD
+0.004+0.52%
Close 07-31 16:00（ET）Quotes delayed by 15 min
58.48MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.52%
5 Days
+3.45%
1 Month
-33.69%
6 Months
-51.12%
Year to Date
-69.56%
1 Year
-67.60%
Key Figures
0.860Open
0.880High
582.35KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.85%Turnover Ratio
0.851Prev. Close
0.830Low
384.73KTurnover
LossP/E Static
1.68P/B
0.00%Div Yield TTM
-66.82%ROA
4.55552wk High
0.57Volume Ratio
-45.45MNet Profit
68.37MShares
-0.6650EPS TTM
1.35Beta
-84.84%ROE
1.48052wk Low
5.88%Amplitude
100.00%Gross Margin
58.48MMarket Cap
-8.19Reward/Risk
4.21%Risk Rate
TradingKey Stock Score of Cardiff Oncology Inc
Currency: USD Updated: 2026-07-31Key Insights
Cardiff Oncology Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 142 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cardiff Oncology Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cardiff Oncology Inc Highlights
StrengthsRisks
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 21.52% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 593.00K.
Overvalued
The company’s latest PE is -1.29, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 24.09M shares, decreasing 30.58% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 11.24K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
7.500
Target Price
+825.93%
Upside Space
Cardiff Oncology Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
8
analysts
Buy
Current Rating
7.500
Target Price
+825.93%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Cardiff Oncology Inc
CRDF
8
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.834
Buy
MA10
0.837
Buy
MA20
1.011
Sell
MA50
1.294
Sell
MA100
1.499
Sell
MA200
1.875
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cardiff Oncology Inc Info
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Ticker SymbolCRDF
CompanyCardiff Oncology Inc
CEOErlander (Mark)
Websitehttps://cardiffoncology.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Cardiff Oncology Inc (CRDF)?
The current price of Cardiff Oncology Inc (CRDF) is 0.86.
What is the symbol of Cardiff Oncology Inc?
The ticker symbol of Cardiff Oncology Inc is CRDF.
What is the 52-week high of Cardiff Oncology Inc?
The 52-week high of Cardiff Oncology Inc is 4.55.
What is the 52-week low of Cardiff Oncology Inc?
The 52-week low of Cardiff Oncology Inc is 1.48.
What is the market capitalization of Cardiff Oncology Inc?
The market capitalization of Cardiff Oncology Inc is 58.48M.
Is Cardiff Oncology Inc (CRDF) currently rated as Buy, Hold, or Sell?
According to analysts, Cardiff Oncology Inc (CRDF) has an overall rating of Buy, with a price target of 7.50.
What is the Earnings Per Share (EPS TTM) of Cardiff Oncology Inc (CRDF)?
The Earnings Per Share (EPS TTM) of Cardiff Oncology Inc (CRDF) is -0.69.